Roche commits $190 million upfront to license Hanmi's early-stage muscle-building obesity drug, total deal up to $2.3 billion

Roche announced it will pay $190 million upfront to license an early-stage obesity drug from South Korean company Hanmi Pharm. The compound is described as a non-incretin, muscle-building therapy aimed at treating obesity.

The agreement includes potential milestone payments that could bring the total value of the partnership to about $2.3 billion. This deal adds to a series of recent obesity collaborations that Roche has pursued.

By expanding its portfolio with this candidate, Roche aims to strengthen its position in the rapidly growing obesity market, where demand for new treatment mechanisms remains high.